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ORIGINAL ARTICLE
Exogenous miR-29B Delivery Through a Hyaluronan-Based
Injectable System Yields Functional Maintenance
of the Infarcted Myocardium
Michael G. Monaghan, PhD,1–3 Monika Holeiter, PhD,1,2 Eva Brauchle, PhD,1,2 Shannon L. Layland, MBA,1,2
Yan Lu, PhD,4 Arjun Deb, MD,4 Abhay Pandit, PhD,5 Ali Nsair, MD,4 and Katja Schenke-Layland, PhD, MSc1,2,4
Myocardial infarction (MI) results in debilitating remodeling of the myocardial extracellular matrix (ECM). In
this proof-of-principle study it was sought to modulate this aggressive remodeling by injecting a hyaluronic
acid-based reservoir delivering exogenous microRNA-29B (miR-29B). This proof-of-principal study was ex-
ecuted whereby myocardial ischemia/reperfusion was performed on C57BL/6 mice for 45min after which five
10 mL boluses of a hydrogel composed of thiolated hyaluronic acid cross-linked with poly (ethylene glycol)
diacrylate, containing exogenous miR-29B as an active therapy, were injected into the border zone of the
infarcted myocardium. Following surgery, the myocardial function of the animals was monitored up to 5 weeks.
Delivering miR-29B locally using an injectable hyaluronan-based hydrogel resulted in the maintenance of
myocardial function at 2 and 5 weeks following MI in this proof-of-principle study. In addition, while animals
treated with the control of a nontargeting miR delivered using the hyaluronan-based hydrogel had a significant
deterioration of myocardial function, those treated with miR-29B did not. Histological analysis revealed a
significantly decreased presence of elastin and significantly less immature/newly deposited collagen fibers at the
border zone of the infarct. Increased vascularity of the myocardial scar was also detected and Raman micro-
spectroscopy discovered significantly altered ECM-specific biochemical signals at the border zone of the
infarct. This preclinical proof-of-principle study demonstrates that an injectable hyaluronic acid hydrogel
system could be capable of delivering miR-29B toward maintaining cardiac function following MI. In addition,
Raman microspectroscopy revealed subtle, yet significant changes in ECM organization and maturity. These
findings have great potential with regard to using injectable biomaterials as a local treatment for ischemic tissue
and exogenous miRs to modulate tissue remodeling.
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Introduction
Worldwide, coronary artery disease is the singlemost frequent cause of death, which is increasing
with 7.4 million people dying each year, accounting for
13.2% of all deaths.1 It is estimated that every sixth man
and every seventh woman will die from myocardial in-
farction (MI) in Europe.2 Despite significant advances in
post-MI therapies, surviving patients often develop chronic
heart failure, a severe condition with high mortality and mor-
bidity rates, affecting more than 24 million people worldwide.2
The adult mammalian heart has negligible regenerative
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capability; therefore, a highly aggressive alteration of
cardiac tissue compensates the loss of cardiomyocytes
following MI leading to fibrotic scar formation and debil-
itating remodeling, inevitably resulting in a loss of con-
tractile myocardium.3 An increased synthesis of fibrillar
type I and type III collagens becomes morphologically
evident at week 1 post-MI and their organized assembly in
the form of scar tissue is evident at week 2, which continues
to accumulate over 8 weeks.4 This excessive accumulation
of extracellular matrix (ECM) proteins in the interstitial
and perivascular regions of the myocardium during car-
diac fibrosis is a hallmark of maladaptive hypertrophy and
heart failure.3
A disruptive imbalance of microRNAs (miRs) occurs
within the myocardium that is intimately coordinated with
the heart’s response to MI.5 miRs are a vital and evolu-
tionary component of gene regulation and serve to post-
transcriptionally silence mRNAs through translation inhibition
and degradation.6 miR-29B has been specifically associated
with the regulation of fibrosis in a number of tissues, in-
cluding renal, bone,7 pulmonary, hepatic,8 and cardiac tis-
sue,9 and has also been elucidated to play a significant role
in ECM remodeling, possessing a significant relationship
with collagen production.9,10 It has been collectively shown
that the miR-29 family members target at least 16 genes
related to ECM, which encode for several key proteins in-
volved in physiological or pathological formation of ECM,
including a large number of collagen isoforms, laminin g,
fibrillin 1, elastin, MMP 2, and integrin b1.9,11 This is un-
ique to the miR-29 family as no other miR is predicted to
target more than 11 of the 20-collagen genes. In cultured
cardiac fibroblasts, miR-29 has been downregulated after
TGF-b1 stimulation, suggesting that the decrease in miR-29
in the pathological remodeling of the heart is mediated by
TGF-b1.
9 Van Rooij et al. were the first to show that the
miR-29 family directly targets a multitude of ECM genes
such as collagens type I and III, elastin, and fibrillins.9 The
reported downregulation of miR-29 in several cardiac pa-
thologies suggests that this loss may actually contribute to
the development of cardiac fibrosis by relieving its repres-
sion on ECM gene expression. Knockdown of miR-29B by
antisense oligonucleotides (antagomiRs), designed to block
miR-29B in the healthy mouse heart, has resulted in in-
creased expression of ECM genes at the mRNA level, but it
is unclear whether this was sufficient to induce excessive
fibrosis.9 Using miRs as therapeutics has recently gathered
interest as miR mimics and antagomiRs can be easily pro-
duced and synthesized, and the mechanism by which they
function requires cellular entry rather than nuclear insertion
(as is the case for plasmid DNA).12,13
This proof-of-principle study hypothesizes that the de-
livery of exogenous miR-29B following MI will contribute
toward an improved functional recovery of the myocardium
through modification of the deposited ECM. To ensure a
localized delivery, minimizing off-target effects on other
organs, we aimed to deliver miR-29B at the border zone of
the infarct using an injectable hydrogel based on thiol-
modified hyaluronan, cross-linked with poly (ethylene-glycol)
diacrylate. In addition, Raman microspectroscopy was used
as a complimentary tool to detect changes in ECM orga-
nization and maturity not detectable by marker-depended
conventional methods.
Materials and Methods
Hyaluronan-based hydrogel/miR fabrication
Glycosan HyStem (BioTime, Inc.), a thiolated hyaluronan-
based hydrogel cross-linked using thiol-reactive poly(ethylene
glycol) diacrylate, was diluted with phosphate-buffered sa-
line (PBS; 13:2 ratio, PBS:HyStem). miR-29B and miR-
239B mimics (negative control, which has been confirmed
to have minimal sequence identity with miRs in human,
mouse, and rat) were obtained from Dharmacon with the
sequences for:
cel-miR-239B: 5¢-uuuguacuucggcuaaggugcug-3¢ (non-
targeting control)
mur-miR-29B: 5¢-uagcaccauuugaaaucaguguu-3¢
and reconstituted in the PBS and mixed with the hydrogel
solution (13:2) to achieve a final miR concentration of 140mM
of miR mimics (Fig. 1). Hydrogel solutions were prepared
directly before injection to prevent premature gelation,
whereby at room temperature gelation occurs within 20min.
Ischemia/reperfusion studies
Animal care and surgeries were performed in compliance
with the University of California Los Angeles Animal Re-
search Committee under protocols 2011-042 and 2013-057.
Ischemia/reperfusion was conducted on C57BL/6 mice
(20 – 1.2 g body weight) through ligation of the left anterior
descending (LAD) artery as previously described.14 Briefly,
three animals per group were anesthetized with isoflurane,
and a left thoracotomy under mechanical ventilation using a
volume cycled rodent ventilator (Harvard MiniVent) was
performed. The LAD coronary artery was ligated intramu-
rally, 2mm from its origin using a 9-0 nylon suture. A small
plastic tube (PE-10) was placed between the ligated vessel,
and the node was left tightened against the LAD for 45min
whereby ischemia was verified by subsequent blanching of
the myocardium. Reperfusion was accomplished by cutting
the knot on the PE-10 tube and confirmed by hyperemia of
the previously pale ischemic region.
Animals received serial injections of 10mL volumes of
hydrogel solution (containing miR-29B or the control of
miR-239B) into five sites at the infarction border zone
(total = 50 mL), identified by regional blanching of the
myocardium. As controls, 10 mL volumes of hydrogel so-
lution (containing no miRs) and 10 mL volumes of saline
were injected into five sites at the infarction border zone
(total = 50 mL). The veterinary surgeon administered the
treatments in a blinded manner. After confirmation of no
internal bleeding, the chest was closed in two layers as
follows: first the ribs (inner layer) were closed with 6-0
coated Vicryl sutures in an interrupted pattern, and the
skin was closed using 6-0 nylon or silk sutures in a sub-
cuticular manner. The anesthesia was removed, and the
animals were allowed to recover respiration before the
endotracheal tube was removed. All mice received 2.5mg/kg
Banamine postsurgery.
Echocardiography
Mice were assessed echocardiographically presurgery
to establish a pretreatment baseline and again at the time
points of 2 days, 2 weeks, and 5 weeks postsurgery to
track cardiac function using a high-frequency ultrasound
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system (Vevo2100; FujiFilm VisualSonics, Inc.). This was
performed by the same veterinary surgeon who administered
the treatments, who was therefore unaware of the treatment
each animal received. Image acquisition was performed at
a high frame rate (>200 frames/s) to ensure an adequate
quality of the images and for at least three cardiac cycles per
loop where breathing artifacts were absent or minimized.
Animals which exhibited incomplete ischemia at day 2 were
removed from the study.
Histology and immunofluorescence staining
Animals were sacrificed at 5 weeks following MI. Fol-
lowing morphometric planimetry, explanted hearts were
fixed for 12 h in 10% formalin, subjected to gradual serial
dehydration, and embedded in paraffin. Entire hearts were
then sectioned into 3mm thick sections. For general mor-
phology serial sections (every tenth section) were depar-
affinized in xylene, rehydrated through graded ethanol
FIG. 1. (A) Schematic of the MI model and hyaluronan-based delivery system used in this study. (B) Thiol-modified
hyaluronic acid was reacted with PEGDA to form a hydrogel solution. (C) miR mimics were mixed with the hydrogel
solution and prepared in an insulin syringe. (D) The hydrogel/miR mimic mixture was injected into the border zone of
infarcted myocardium following ischemia/reperfusion injury. (E) Hypothesized behavior and release kinetics of miRs from
the injected hydrogel over time. As the hydrogel (blue) is injected into the border zone of the infracted myocardium, cells
and ECM present at this location become exposed to the injected treatment. Over time (t), it is possible that degradation of
the hydrogel in combination with release of miR mimics from the hydrogel results in the highest concentration of miR
mimics being present close to the site of injection at the border zone with reduced presence further away from the injection
site. MI, myocardial infarction; miR, microRNA; PEGDA, poly (ethylene glycol) diacrylate.
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washes (100–70% v/v) to water, and stained in 0.1% fast
green (pH 7, Fast Green FCF; Sigma Aldrich) for 30min
followed by staining in 0.1% Sirius red in saturated picric
acid (picrosirius red stain) for 1 h. Following this, the sec-
tions were rapidly dehydrated through graded ethanol wa-
shes (70–100% v/v) and mounted. Bright field and
orthogonal images were taken at 63 · and 40·magnification
with a light microscope Observer.Z1 (Carl Zeiss GmbH).
After identification of the infarcted tissue sections, the area
of the fibrous infarcted myocardium was calculated as the
percentage of the picrosirius red-stained collagen in the
myocardium per total area of tissue (picrosirius red- and fast
green-stained tissue) using bright field images. Features
such as the cardiac valves were omitted from these calcu-
lations. Areas were calculated using threshold analyses us-
ing ImageJ (freely available from www.nih.org).
For immunofluorescence staining, sections were depar-
affinized in xylene, rehydrated through graded ethanol washes
(100–70% v/v) to water, and heat mediated antigen retrieval
was performed using a microwaveable pressure cooker as
previously described.15 The following primary antibodies and
dilutions were used for immunohistological staining: cardiac
troponin T (cTnT; Sigma Aldrich, HPA015774, 1:3000),
platelet endothelial cell adhesion molecule-1 (CD31; Dianova
GmbH, DIA-310, 1:20), FITC-conjugated alpha smooth
muscle actin (Sigma Aldrich; F3777, 1:500), collagen type I
(Acris Antibodies GmbH; R1038, 1:75), lumican (Abcam Plc;
ab168348, 1:500), and fibulin 5 (a kind donation from
Prof. D. Reinhardt,16 1:500). In all cases, isotype controls
were included using only the antibody dilution buffer. The
secondary antibodies, Alexa Fluor (Invitrogen/Thermo
Fisher Scientific) goat anti-rabbit (594), goat anti-rat (647),
and goat anti-rabbit (488), were used for immunofluores-
cence staining: all at a dilution of 1:250. After secondary
antibody incubation, all sections for immunofluorescence
were exposed to a 4¢,6-diamidino-2-phenylindole (DAPI)
solution for 10min followed by mounting using ProLong
Gold antifade mounting medium (Molecular Probes, Life
Technologies). A minimum of 10 tissue sections were
prepared during each staining procedure for imaging
analysis.
Image analysis
Blood vessel density was quantified using pictures from
immunofluorescence staining of CD31, cTnT, and aSMA.
Measurements were facilitated using ImageJ. The blood
vessel density was calculated using the formula:
blood vessel density¼ number of blood vessels
scar area
Ages of immunofluorescence-stained sections utilizing an-
tibodies against lumican, elastin, collagen type I, and fibulin
5 were analyzed and quantified through the calculation of
the gray value intensities (GVI) using ImageJ. The scar
region was circumscribed in each image and the GVI within
this selected area measured. This was easily discernable
using cTnT staining (where present) and also autofluorescence
emanating from cardiomyocytes. GVI were then calculated
using the measure function of ImageJ, which provides the
mean GVI within the selected area.
Directionality of the collagen fibers
Directionality analysis was performed on the birefrin-
gence images to observe the percentage of alignment of
collagen fibers using a directionality plugin based on a Fast
Fourier Transform analysis with ImageJ. In detail, collagen
tissue shows a better alignment when arranged under strain.
As the tissue’s birefringence is along the direction of strain,
it can be estimated as a linear retarder whose fast axis is
aligned in the direction of strain.17
Raman microspectroscopy
Paraffin-embedded tissue sections (each 10mm thick) were
deparaffinized and analyzed using Raman microspectroscopy.
A custom-built Raman microspectroscopy system was used
for all measurements as previously described.18 Using an
automated stage, spectra were automatically acquired from 35
randomly selected points throughout the tissue. This was
performed in triplicates for every sample. A total acquisition
time of 100 s was used for each spectrum. Raman spectra
were acquired in the wave number range of 0–2000 cm-1 and
recorded using the Andor software package (Andor iDus). All
measurements were performed from specimens mounted on
glass slides. The glass background signal was subtracted from
the samples signal using the OPUS software 4.2 (Bruker
Optik GmbH). In addition, OPUS software 4.2 was used to
segment the Raman spectra into the 400–1800 cm-1 spectral
region, whereby baseline correction and vector normalization
were performed. All samples were investigated at two regions
of the myocardial scar; namely, the center of the infarct and
the transition zone between the fibrotic infarct and healthy
myocardium (border zone).
Statistical analysis
Results are depicted throughout as means – standard de-
viation. Statistical analysis was performed using Prism
(GraphPad Software). Student’s t-test or one-way ANOVA
was performed where appropriate to determine statistically
significant differences among the miR-29B treatment, the
control miR-239B treatment, and the additional controls of
hydrogel with no miRs and saline alone injections. Statis-
tical significance was defined at p< 0.05.
Results
Delivering miR-29B through an injectable hydrogel
scaffold improves functional recovery following MI
Delivering miR-29B intramyocardially through a hyaluronan-
based scaffold at the border zone yielded a significantly
improved myocardial function at the follow-on time points
of this proof-of-principle MI study (Fig. 2) compared with
the treatment of the nontargeting miR-239B control. Speci-
fically, mice treated with miR-29B had a significantly higher
ejection fraction compared with mice treated with miR-239B,
at 2 and 5 weeks post-MI (nontargeting mammalian control)
(Fig. 2A, 51.38%– 3.19% vs. 43.70%– 0.67% and 52.02%–
4.14% vs. 42.82%– 3.23%, respectively; p< 0.05). A signif-
icant improvement was also observed at 5 weeks in the as-
sessment of fractional shortening (Table 1, 25.58%– 3.02%
vs. 20.37% – 1.72%; p < 0.05) and fractional area change
(Table 1, 45% – 6.93% vs. 30%– 1%; p < 0.05). Moreover,
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while the ejection fraction of the mice treated with miR-
239B significantly deteriorated at 2 and 5 weeks post-MI
compared to the ejection fraction at 2 days post-MI, mice
treated with miR-29B had no significant deterioration in
ejection fraction and exhibited a slight trend toward an
improved ejection fraction over time. Infarcts treated with
hyaluronan-based hydrogels containing no miRs had simi-
lar ejection fractions to those treated with hydrogels con-
taining the nontargeting miR-239B control (Supplementary
Fig. S1; Supplementary Data are available online at www
.liebertpub.com/tea). This is significant, in that it highlights
the functional specificity of miR-29B and the reliability of
the nontargeting miR-239B as a control. In addition, mice
treated with just saline injections had significantly reduced
ejection fractions (Supplementary Fig. S1) compared with
any of the hyaluronan-based hydrogel treatments (with or
FIG. 2. (A) Morphometric data at 2 dpi
and 2 and 5wpi with treatment of miR-239B
(control) or miR-29B. Asterisk (*) indicates
a statistically significant improvement in EF.
# Indicates a statistically significant dete-
rioration in the cardiac function of animals
treated with miR-239B when compared to
the initial measurement at 2 days post in-
farction (p < 0.05). (B) Quantification of scar
area as a percentage of the total tissue cross
section. No significant difference was de-
tected between miR-239B and miR-29B at 5
weeks post ischemia. Picrosirius red/fast
green-stained sections of hearts treated with
(C) miR-239B and (D) miR-29B. Scale bar:
2mm. Red staining in the ventricular tissue
represents fibrotic ischemic scar tissue at 5
weeks. dpi, days postinfarction; EF, ejection
fraction; wpi, weeks postinfarction.
Table 1. Morphological Data Obtained from Echocardiographic Measurements
from Animals Treated with miR-29B and miR-239B (Control)
Preinfarction 2 dpi 2 wpi 5wpi
Fractional shortening (%) miR-29B 59.7 – 5.5 23.7– 0.8 25.2 – 2.2 25.6 – 3a
miR-239B 67.3 – 4.4 23.3– 0.7 20.7 – 0.7 20.4 – 1.7
Fractional area change (%) miR-29B 57.7 – 2.5 37– 4.4 43.3 – 5.1 45 – 6.9a
miR-239B 64 – 6.7 33– 8 31.3 – 6.7 30 – 1
Heart rate (BPM) miR-29B 563.7 – 49.1 564.– 29.2 553. – 93.9 535.2 – 36.3
miR-239B 569.8 – 29.9 551.5– 43.3 594.3 – 43.3 537.2 – 23.6
Heart mass (mg) miR-29B 43.5 – 6.4 36– 6.3 35.7 – 3.7 36.8 – 12.3
miR-239B 46.8 – 8.5 32.59– 8.4 37.1 – 15.6 47.4 – 17.6
End systolic volume (mL) miR-29B 2.2 – 1.2 17.3– 3.02 14.6 – 3.9 15.4 – 7.2
miR-239B 1.3 – 0.6 15.6– 5.3 21. – 11.5 22.8 – 6.6
End diastolic volume (mL) miR-29B 21.5 – 4.3 33. – 6.5 30.4 – 10.4 33.1 – 18.5
miR-239B 21.2 – 4.5 30.3– 10.3 37.5 – 20.8 39.7 – 9.8
aIndicates a statistically significant improvement in fractional shorting and fractional area change with treatment of miR-29B when
compared with the control treatment of miR-239B at the time points indicated (p < 0.05).
BPM, beats per minute; dpi, days postinfarction; wpi, weeks postinfarction.
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without miRs), which demonstrate the therapeutic benefit of
injecting ECM-based biomaterials into the infarcted myo-
cardium. Based on these findings, we sought to elucidate
the underlying reason as to why miR-29B was generating the
most beneficial outcome. For this reason, we focused the
histological evaluations on infarcts treated with hyaluronan-
based hydrogels containing miR-29B and the nontargeting
miR control (miR-239B).
miR-29B delivery elicits a significantly altered
maturation of collagen fibers and reduced
production of elastin at the border zone
of the infarcted myocardium
We next sought to determine the source of the functional
recovery of animals treated with miR-29B. We therefore
investigated the size of the remodeled fibrotic myocardium
(Fig. 2C, D). Interestingly, using stereological approaches,
we detected no significant difference between the size of
myocardial scars in the miR-239B- and miR-29B-treated
mice (Fig. 2B). Considering the impact of the scar on car-
diac function and yet not detecting any significant difference
in the size of the scar between treatments, we decided to
investigate deeper the quality of the resulting scar regarding
its orientation and ECM composition. With this in mind, we
viewed picrosirius/fast green-stained tissue sections, with
particular focus on the center and border zone of the infarct
under orthogonal light (Fig. 3A). Collagen fibers are bire-
fringent, a characteristic that is enhanced by picrosirius
staining, and it is widely reported that thicker more mature
collagen fibers (namely type I collagen fibers) polarize using
this method toward a stronger red/orange birefringence and
thinner fibers toward a weaker green birefringence.19,20 The
intensely positive birefringence of collagen is caused by the
superimposed right-handed superhelix of the left handed
helix consisting of the three polypeptide chains, yielding
a consequent alignment of the amino acid chains approxima-
tely parallel to the molecular axis.19 According to Hirshberg,21
greenish yellow collagen fibers can represent procollagen,
intermediate, or pathological collagen fibers. Quantification
of the presence of mature (red/orange) and immature (green)
fibers revealed no significant difference between the infarcts
treated with miR-29B or miR-239B (Fig. 3B). Remarkably,
however, we detected a statistically significant difference in
the proportion of mature/immature fibers in the border zone
of the infarcts treated with miR-29B compared with miR-
239B. Namely, the border zone of the infarcts treated with
miR-29B had increased mature fibers and less immature
fibers compared with miR-239B-treated infarcts (Fig. 3B).
Investigating the directionality of these fibers however re-
vealed no significant difference in fiber orientation at either
the border zone or center of the infarcts when compar-
ing miR-29B-treated to miR-239B-treated hearts (Fig. 3C).
As picrosirius red is a general collagen stain, we then per-
formed immunofluorescence staining for collagen type I
(Fig. 4A), yet found no significant difference in its quantity
(determined by assessing GVI, Fig. 4B) within the infarct, at
the border zone of the infarct, or the interstitium of the
remote myocardium. We investigated several other ECM
components present in fibrillogenesis, but found no
FIG. 3. Analysis of scar fiber orientation and quality. (A) Bright field microscopy of picrosirius red/fast green-stained
sections in high magnification and with microscopy of the same regions of interest under orthogonal polarized light to
enhance birefringence of collagen fibers. Scale bar: 100 mm. (B) Quantification of birefringent fibers using color threshold
segmentation for mature fibers (red/orange) and immature fibers (green). A statistically significant increased proportion of
immature fibers and decreased proportion of mature fibers were revealed at the border zone of infarcts treated with the miR-
239B (control) compared with infarcts treated with miR-29B (*p< 0.05). (C) Quantification of fiber orientation with respect
to the center and the border zone of the infarct. No statistically significant difference was detected in the percentage of fibers
orientated to the myocardial wall with miR-29B-treated infarcts compared with miR-239B-treated infarcts.
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significant difference in the expression of these proteins
after GVI quantification (lumican and fibulin 5, Supplemen-
tary Fig. S2).
As miR-29B is a known suppressor of elastin production,9
we sought to evaluate the elastin presence of the myocardial
scar at both the center and border zone of the infarct (Fig. 5A).
Much like findings from the quantification of polarized fibers,
we detected a statistically significant difference at the border
zone of the infarcted myocardium with the treatment of miR-
29B (Fig. 5B). Herein, we detected a significant reduction
in elastin expression (through quantification of GVI of elastin
immunofluorescence staining) in miR-29B-treated hearts
compared with miR-239B (control)-treated hearts (Fig. 5A–C,
2.983–0.6764 vs. 4.396–0.3207GVI/mm2). No significant
difference in elastin expressionwas detected between the centers
of the infarcts of these treatments. In addition, we investigated
the vascularity of the remodeled myocardial scar by evaluation
of blood vessel densitywithin the scar tissue (Fig. 5C).Although
no statistically significant difference was detected, there was a
strong trend toward increased blood vessel density at both the
FIG. 4. (A) Immunofluorescence micrographs of cardiac sections stained for collagen type I (green) with nuclear
counterstaining using DAPI (white) and imaged within the infarct, at the border zone and at the remote myocardium (Rem
Myo). Scale bar: 100 mm. (B) The graph presents quantification of GVI from the collagen type I staining. No statistically
significant difference was detected between the collagen expression of miR-29B samples compared with miR-239B (control
samples). DAPI, 4¢,6-diamidino-2-phenylindole; GVI, gray value intensities.
FIG. 5. (A) Immunostaining and (B) quantification of elastin expression in infarcts treated with miR-29B and miR-239B.
Scale bar: 100 mm. A significantly decreased presence of elastin was revealed in the border zone of infarcts treated with the
miR-29B compared with infarcts treated with miR-29B (*p < 0.05). (C) Immunostaining for detection of blood vessel
density within myocardial scars and (D) quantification of vessel density within myocardial scars. A strong trend was
detected toward increased vascularity at both the border zone ( p = 0.19) and center of the infarcts ( p = 0.09) of hearts treated
with miR-29B compared with control treatments (miR-239B).
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border zone and the center of the infarct of the miR-29B-treated
hearts ( p=0.19 and p=0.09, respectively, Fig. 5D).
Raman microspectroscopy reveals significantly
altered ECM-related peaks at the border zone
of the infarcted myocardium
To reliably detect subtle changes in ECM maturity and
orientation, we used Raman microspectroscopy to obtain a
biomolecular fingerprint to gain more information regarding
the ECM at the border zone of miR-29B-treated infarcts
with respect to the presence and quality of specific ECM
components and their relative abundancies. Raman micro-
spectroscopy has been used to distinguish various stages of
cardiomyogenic differentiation,22 as well as detecting changes
in ECM constituents after remodeling.23 Thus, by comparing
between samples, changes in the ECM can be revealed.Within
this study, we detected significant differences in the Raman
spectra at distinct regions of the infarcted myocardium, namely
the center of the infarct and the border zone (Fig. 6 and Sup-
plementary Fig. S3). Interestingly, a greater number of
spectra were significantly different at the border zone, which
is where the miR-loaded hydrogel solutions were injected
at the point at which infarction was induced. A large pro-
portion of these reduced spectral peaks can be attributed to
collagen24 (Table 2), whereby the signals of these peaks
were significantly decreased with the treatment of miR-29B
compared with the control of miR-239B. In addition, the
peaks of desmosine/isodesmosine, which are elastin cross-
linking amino acids,25 were significantly reduced in the miR-
29B-treated border zones compared with the miR-239B
controls, which is supportive of the quantification of elastin
expression (Fig. 5A, B).
Discussion
Adverse ECM remodeling following MI remains still a
considerable contributor toward end-stage heart failure.2 This
study demonstrates the effectiveness of delivering exogenous
miR-29B to the infarcted myocardium to affect localized
FIG. 6. Raman spectra acquired at the center (A) and the border zone of the infarct (B) at 5 weeks post-MI in miR-239B- and
miR-29B-treated samples. Vertical lines indicate spectra of interest, which revealed spectral differences between the treatments.
Table 2. Significantly Different Peaks Detected Between miR-239B (Control) and miR-29B
at the Center and the Border Zone of the Infarct
Center of infarct Border zone of infarct Peaks in literature assignment
452, 453, 455 — 454: ring torsion of phenylalanine
522 525 524: S-S disulfide stretching band of collagen
— 763 760: ring breathing tryptophan (proteins)
860 858, 859, 860 859: tyrosine of collagen
862, 863 862, 863, 865, 866 820–930: CeC stretch of proline and hydroxyproline
— 881 884: proteins, including collagen I
— 935, 937, 938, 940, 941, 942 928–940: CeC vibrations of proline and backbone
— 948, 950, 953 950–951: CH3 deformation in proteins (a-helix)
— 964 963: CH bending in proteins
— 967 966: desmosine/isodesmosine
— 1127 1128: CeN stretching
— 1155 1155: CeC, CeN stretching in proteins
1305 — 1302–1314: CH2 twisting and wagging in collagen
— 1506, 1508 1506: N]H bending
1518, 1521 — 1518–1520: C]C stretching
1573 — 1573: tryptophan
1580 — 1580: CeC stretching
1600, 1601 — 1600: amide I band of proteins due to C]O stretching
1610 — 1610: NH2
1737 — 1736: C]O
Detected peaks were assigned according to previously published reports.30
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delivery and address adverse myocardial remodeling by
harnessing endogenous molecules.5 In previous studies, ex-
ogenous miR-29B has been demonstrated to reduce fibrosis in
other settings,12,26–28 yet this is the first reported demonstra-
tion in an MI model and specifically using a localized bio-
material delivery system (in this case a hyaluronan-based
hydrogel). Although we found significant cardiac functional
improvements following the administration of miR-29B using
an injectable hyaluronic acid hydrogel, we did not identify
the significant difference in the size of the ventricular scar
between the miR-29B treatment and miR-239B controls an-
ticipated. However, it should be reiterated that this proof-of-
principle study has a low number of animals and therefore
expanding this into a full investigation with a larger number
of animals could reveal a statistically significant effect of the
miR-29B treatment on ECM deposition (particularly collagen
type I) and other parameters.
It is accepted that the constituents of the scar play a sig-
nificant role in the compliance of scar tissue and contribution
toward functional support following MI.29 Therefore, we
sought to seek out more information regarding the compo-
nents of the scar ECM. Although immunostaining did not
reveal the significant difference in the collagen content within
the center of the scar or at the border zone of the scar or at the
remote myocardium that was anticipated (Fig. 4), polarized
light microscopy revealed a significantly reduced presence of
green immature fibers at the border zone of hearts treated with
miR-29B compared with hearts treated with miR-239B. This
corresponds to a significantly increased presence of red/
orange, more mature collagen fibers at the border zone of miR-
29B-treated infarcts. These mature collagen fibers are stron-
ger and were aligned circumferentially with the myocardial
wall, which gives compensatory support to the infarcted
myocardium. Biomaterial scaffolds are capable of having a
spatiotemporal release of therapeutics that is responsive to the
biomaterial diffusion properties and interaction with a sup-
porting host environment.6,23 The same applies in this study
whereby we hypothesize that following MI and hydrogel in-
jection, the overlapping phases of repair and tissue remodeling
do occur within the infarcted myocardium leading to the
synthesis of newly deposited ECM. However, later on,
during hydrogel degradation and subsequent release of the
therapeutic miR, additional collagen fiber formation and
maturation is modulated, and most potently, at the border
zone of the infarct, where the hydrogel had been delivered
(Fig. 1E). The Raman microspectroscopy data were suffi-
ciently sensitive toward detecting subtle changes in ECM
orientation and maturity, whereby a more profound number
of spectral peaks were significantly different in the border
zone than the center of the infarct when comparing miR-
239B- and miR-29B-treated hearts (25 vs. 16 peaks, Fig. 6,
Supplementary Fig. S3 and Table 2).30 In addition, elastin
production was significantly reduced at the border zone of
infarcts treated with miR-29B compared to those treated
with miR-239B (Fig. 5A–C, 2.983 – 0.6764 vs. 4.396 –
0.3207GVI/mm2). This is important as it is widely estab-
lished that miR-29B inhibits translation of the elastin gene
ELN.31 As elastin is known to be a pliable structure, and
we detected more mature collagen fibers at the border zone
of miR-29B-treated infarcts, we hypothesize that the bor-
der zones of the miR-29B-treated infarcts are stiffer than
those of the miR-239B-treated infarcts.
The injection of biomaterial scaffolds does have an impact
on myocardial remodeling and many different scaffolds have
been injected into infarcted myocardium in previous studies,
resulting in improvement in ventricular function due to ven-
tricular thickening.32 Clinical trials with alginate as an in-
jectable material treating MI have now been reported,33
yielding positive results in the first-in-man trials.34 The use of
the hyaluronan-based hydrogel with no miR was considered
in this study (Supplementary Fig. S1). Hydrogels with miR-
29B embedded still yielded a significant improvement in
cardiac function compared with empty hydrogels, which
signifies that this particular miR sequence is responsible for
the improvements detected in cardiac function. Infarcts
treated with hydrogels containing no miRs had a similar
ejection fraction to infarcts treated with hydrogels containing
the nontargeting miR-239B (Supplementary Fig. S1). In
general, infarcts treated with only the hyaluronan-based hy-
drogel had a greater ejection fraction than infarcts treated
with saline only, which demonstrates that in this instance, the
injection of the hydrogel alone was itself, contributing a
beneficial effect. This adds strength to the observations of this
study such that injectable biomaterials are suitable for cardiac
repair and are also suitable for delivering beneficial biomol-
ecules such as miRs. The use of such a hydrogel reservoir of
miR-29B is advantageous in achieving targeted delivery, but
also a localized release of miR-29B. There are extensive re-
ports of hyaluronic/PEG hydrogels whereby they have been
used as carriers factor cells35,36 and nonviral gene therapeu-
tics.35 For the most part, these investigations have been done
in vitro, and the release profiles have been evaluated using
PBS or hyaluronidase. In these studies, it was reported that
burst release profiles can range from 20% to 65% in the first
2 days in the presence of PBS and burst release profiles
ranged from 40% to 70% in the presence of hyaluronidase.
Although the translation of in vitro release profiles to an
in vivo situation is extremely difficult, we can assume that the
miRs penetrate the infarct border zone tissue through the
processes of hyaluronan degradation, PEG degradation, miR
diffusion from the hydrogel, and the local tissue response.
The use of the hyaluronan-based hydrogel in combination
with miR-29B in this study led to a tendency of increased
blood vessel density at the border zone and center of the
infarcts (Fig. 5D). It is important that the quantification of
blood vessel density involved the identification of vessels
containing both endothelial, CD31-expressing, and smooth
muscle, a-SMA-expressing, cells as the formation of single
capillaries does not necessarily indicate an increase in blood
flow, due to the ease of regression of vessels without smooth
muscle.37 The injection of hyaluronic acid has been previ-
ously shown to increase angiogenesis in pathological settings
such as MI38 and hind limb ischemia.39 Such reports are in
agreement with the trends observed in this study (although not
statistically significant) that the addition of miR-29B could
have a positive influence on blood vessel formation due to its
effect on ECM remodeling, which could be directly involved
in the formation of blood vessels, or indirectly exerting pos-
itive biomechanical cues from the surrounding ECM.
Overall, the results of this proof-of-principle study pro-
vide robust evidence that miR-29B is a strong candidate
toward modulating the aggressive synthesis of ECM that
aims to compensate the infarcted myocardium. In addi-
tion, the use of an injectable hyaluronan-based system for a
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targeted delivery to elicit a regional effect was effective.
Although strong trends were observed in histochemical an-
alyses using the treatment of miR-29B (e.g., in the case of
increased scar vascularity), statistically significant differ-
ences were not detected, potentially due to the low animal
numbers used in this study. However, Raman microspec-
troscopy was sufficiently sensitive to detect significant differ-
ences in aspects of ECM maturation and structural orientation.
Taking all this into account, this study gives strong evi-
dence regarding the potential of this platform and provides a
basis toward refinement of parameters to be tested in future
evaluations of this platform.
Conclusion
In this study, we have shown that local hydrogel-based
delivery of miR-29B to the infarcted myocardium at the
border zone had a location-specific effect on ECM orientation
and constituency. Collagen deposition was modulated, whereby
the production of new immature collagen fibers at the bor-
der zone was reduced with a treatment of miR-29B. The
deposition of elastin was significantly reduced at the border
zone of the infarcted myocardium when miR-29B was de-
livered, and this group also had a strong tendency toward
increased blood vessel density at both the border zone and
center of the infarcted myocardium. Raman microspectro-
scopy was sufficiently sensitive to detect significant differences
in aspects of ECM maturation and structural orientation,
particularly with regard to the presence of elastin, which is
supportive of the immunohistological elastin data, and dis-
crete molecular changes within collagen fiber structure.
Together, these promising proof-of-principle results dem-
onstrate the feasibility of using injectable ECM-based bio-
materials as local delivery reservoirs of therapeutics, and in
this instance, the miR-29B therapy to modulate the remodel-
ing of the ECM following MI.
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